Scientists at Stanford University have unveiled a detailed laboratory protocol for a high-throughput drug screening platform designed to find compounds capable of treating cardiac fibrosis, the stiffening of heart tissue that accompanies heart attacks, genetic cardiomyopathies, diabetes and aging. Writing in Nature Protocols, the team led by Hao Zhang and Joseph C. Wu describes a workflow built on human induced pluripotent stem (iPS) cell-derived cardiac fibroblasts, engineered with a reporter system that signals fibrotic activity, paired with a counter-screening step in iPS cell-derived cardiomyocytes to weed out drugs that might harm beating heart cells. The work addresses a striking clinical gap: despite the central role fibrosis plays in worsening heart failure and driving mortality, no drug has ever been approved by the US Food and Drug Administration specifically to target cardiac fibrosis.
Fibrosis itself is a double-edged biological process. In response to injury, fibroblasts become activated and deposit excessive amounts of extracellular matrix, the protein scaffold that gives tissues structure. When this deposition spirals out of control, organs stiffen and progressively lose function. In the heart, scar-like tissue replaces working muscle, impairs contraction, disrupts electrical signaling and ultimately contributes to increased morbidity and death. The researchers note that this pathological remodeling is a common feature across ischemic heart failure, genetic cardiomyopathies, diabetes mellitus and the aging heart, making it one of the most consequential targets in cardiovascular medicine.
The reason no approved antifibrotic exists for the heart, the authors argue, is not a lack of biological interest but a lack of reliable, translatable discovery platforms. Traditional approaches often rely on primary fibroblasts harvested from tissue, which are difficult to obtain, do not divide indefinitely, vary between donors and are hard to scale to the tens of thousands of wells needed for modern pharmaceutical screening. Animal studies, for their part, have repeatedly failed to predict human toxicity and efficacy accurately. The new protocol was conceived as a new approach methodology, a term regulators use for non-animal testing strategies that better reflect human biology while remaining scalable.
At the heart of the platform are reporter iPS cell-derived cardiac fibroblasts. Induced pluripotent stem cells can be generated from virtually any patient and then directed to differentiate into quiescent, resting cardiac fibroblasts that closely resemble those found in healthy heart tissue. By inserting a reporter gene whose activity tracks fibrotic activation, the researchers created cells that glow measurably when they switch into the scar-forming, myofibroblast-like state. When a compound suppresses this signal, the assay flags it as a potential antifibrotic hit. Because the cells derive from a renewable stem cell line, they can be produced in the large, uniform batches that automated 384-well plate screening demands.
The workflow is organized in two stages. In the first, the reporter fibroblasts are plated into 384-well plates and exposed to large chemical libraries in a process called quantitative high-throughput screening, a titration-based approach in which every compound is tested across multiple concentrations rather than at a single dose. This design distinguishes genuine, dose-dependent biological activity from noise and artifacts. Before screening begins, the team meticulously optimizes cell density so that the reporter signal sits in a sensitive linear range. The authors report that the complete pipeline, from cell preparation through primary screening, is robust and scalable, capable of screening approximately 5,000 compounds within six to eight weeks.
The second stage is the counter-screen, and it is what sets the platform apart from conventional fibroblast assays. Any compound that quiets fibroblast activation would be clinically useless, or worse, dangerous, if it simultaneously poisons cardiomyocytes, the contractile cells of the heart. To guard against this, the researchers test their initial hits on human iPS cell-derived cardiomyocytes and exclude any molecule with detectable cardiotoxicity. The importance of this step is well documented: earlier studies from the same field showed that iPS cell-derived cardiomyocytes can recapitulate patient-specific susceptibilities to drug-induced heart injury, such as the sensitivity of some breast cancer patients to doxorubicin, and that high-throughput screens can detect electrophysiological hazards like QT interval prolongation that are missed in other preclinical models.
The protocol is not merely theoretical. It distills lessons from the group’s own discovery work, including a 2024 Cell study in which a multiscale version of this screening strategy identified MD2, an innate immune adaptor protein, as a therapeutic target for cardiac fibrosis. That campaign moved from fibroblast-level screening to validation in engineered heart tissues and animal models, illustrating how hits emerging from the platform can be triaged toward deeper mechanistic and preclinical studies. The team has also published methods for generating quiescent cardiac fibroblasts from iPS cells and for building three-dimensional cardiac organoids for antifibrotic screening, creating a family of complementary human-cell models around the same core technology.
What makes the approach broadly exciting is its adaptability. Because iPS cells can be differentiated into fibroblast-like and mesenchymal populations for many organs, including lung, liver and skin, the same screening logic could be repurposed to hunt for antifibrotic drugs for idiopathic pulmonary fibrosis, liver cirrhosis or systemic sclerosis. Indeed, related protocols for generating hepatic stellate cells and lung mesenchyme from pluripotent stem cells have already appeared in the literature. The Stanford team frames their protocol as a versatile template for phenotypic drug discovery, in which compounds are selected for their effect on a disease-relevant cellular behavior rather than against a single molecular target, an industry strategy increasingly valued for its ability to surface unexpected mechanisms.
There are practical caveats for laboratories hoping to adopt the system. Generating and authenticating a reporter iPS cell line requires genetic engineering expertise, and the differentiation protocol to produce quiescent cardiac fibroblasts demands careful timing of developmental signaling cues. Quantitative high-throughput screening also requires access to robotic liquid handling, plate readers and curated compound libraries, resources typically found at dedicated screening centers. The published protocol addresses many of these hurdles with detailed guidance on plate layout, control compounds, data normalization and hit selection criteria, and its figures walk readers through differentiation, optimization and representative screening results step by step.
For patients, the stakes could hardly be higher. Heart failure remains a leading cause of death worldwide, and fibrosis is the common pathway through which many different injuries destroy cardiac function. A reproducible, human-cell-based platform that can rapidly separate genuine antifibrotic candidates from cardiotoxic impostors offers the pharmaceutical industry a translatable bridge between bench chemistry and clinical trials, one that reduces reliance on animal experiments while keeping human biology at the center of the search. As new approach methodologies gain regulatory momentum, protocols like this one may help ensure that the next generation of fibrosis drugs is discovered not in a petri dish of rodent cells, but in human cells reprogrammed to mirror the patients they are meant to save.
Subject of Research: A high-throughput drug screening protocol using human iPS cell-derived cardiac fibroblasts and cardiomyocytes to identify non-cardiotoxic antifibrotic compounds.
Article Title: New approach methodologies: drug screening platform to identify antifibrotic compounds
Article References: Zhang, H., Ren, L., Huang, R., Tan, R., Solow-Cordero, D. E., Mukherjee, S., & Wu, J. C. (2026). New approach methodologies: drug screening platform to identify antifibrotic compounds. Nature Protocols. https://doi.org/10.1038/s41596-026-01445-8
Image Credits: AI Generated
DOI: 10.1038/s41596-026-01445-8
Keywords: cardiac fibrosis, drug screening, induced pluripotent stem cells, cardiac fibroblasts, cardiotoxicity, new approach methodologies, high-throughput screening, phenotypic drug discovery, heart failure, cardiomyocytes, fibrosis, Nature Protocols
Cite Scienmag News
APA MLA Chicago
Copy citation Download RIS
Tags: cardiac fibroblastscardiac fibrosisCardiac tissue engineeringcardiomyocytescardiotoxicitydrug screeningdrug toxicity screening in cardiomyocytesextracellular matrix depositionfibrosisfibrosis detection reporter systemfibrosis-related heart diseaseheart failureheart failure treatment developmenthigh-throughput drug screeninghigh-throughput screeninginduced pluripotent stem cellsinduced pluripotent stem cells (iPS)Nature Protocolsnew approach methodologiesnovel therapies for cardiac fibrosisphenotypic drug discoverystem cell-based disease modelingstem cell-derived cardiac fibroblasts
